High response rate with a lower dose of paclitaxel in combination with cisplatin in heavily pretreated patients with advanced breast carcinoma

Cancer

Volumn 88, Issue 8, 2000, Pages 1863-1868

  Maiche, Abdel G ^a   Jekunen, Antti P ^a   Kaleva Kerola, Jaana ^b   Sequeiros, Guillermo Blanco ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Breast carcinoma; Cisplatin; Clinical trial; Paclitaxel

Indexed keywords

CISPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DOSE CALCULATION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HYPOTENSION; LEUKOPENIA; NAUSEA; POLYNEUROPATHY; PRIORITY JOURNAL; SEPTICEMIA; STOMACH ULCER; TACHYCARDIA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TREATMENT OUTCOME;

EID: 0034655275     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000415)88:8<1863::AID-CNCR15>3.0.CO;2-E     Document Type: Article

References (29)

1. Horowitz SB. Mechanism of action of Taxol. Trends Pharmacol Sci 1992; 13:134-6.
2. Gelmon K. The taxoids: paclitaxel and docetaxel. Drug Profile 1994;344:1267-72.
3. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992;18:646-62.
4. Holmes FA, Walters RS, Theriault RL. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
5. Holmes FA, Frye D, Valero V. Phase 1 study of Taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1992;11:60.
6. Wilson WH, Berg S, Bryant G, Wittes RE, Bates S, Fojo A, et al. Paclitaxel in doxorubicin-refractory or mitoxantrone refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994;12:1621-9.
7. Fisherman JS, McCabe M, Noone M, Ognibene FP, Goldspiel B, Venson DJ, et al. Phase I study of taxol, doxorubicin, plus granulocyte colony-stimulating factor in patients with breast cancer. Monogr Natl Cancer Inst 1993;15:189-94.
8. Gehl J, Boesgaard M, Paaske T, Jensen BV, Dombernowsky P. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996;7:687-93.
9. Arbuck SG, Dorr A, Friedman MA. Paclitaxel (Taxol) in breast cancer. Hematol Oncol Clin North Am 1994;8:121-40.
10. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 1994;21:29-33.
11. Gelmon KA. Biweekly paclitaxel and cisplatin in breast and ovarian cancer. Semin Oncol 1994;21:24-8.
12. Rose WC. Taxol-based combination therapy and other in vivo preclinical antitumor studies. Monogr Natl Cancer Inst 1993;15:47-53.
13. Greco FA, Hainsworth JD. Paclitaxel (Taxol): Phase I/II trial comparing 1-hour infusion schedules. Semin Oncol 1994;21: 3-8.
14. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994;69:299-306.
15. Rowinsky EK, Chaudhry V, Cornblath DR, Donehower RC. Neurotoxicity of Taxol. Monogr Natl Cancer Inst 1993;15: 107-15.
16. Kodali S, Burkley M, Nag K, Taylor RC, Mougdil VK. Taxol and cisplatin inhibit proliferation of T47D human breast cancer cells. Biochem Biophys Res Commun 1994;202:1413-9.
17. Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al. A reassessment of cardiac toxicity associated with Taxol. Monogr Natl Cancer Inst 1993;15:117-30.
18. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 1994;35:304-11.
19. Jekunen AP, Heikkilä P, Maiche AG, Pyrhönen S. Paclitaxel-induced myocardial damage detected by electron microscopy. Lancet 1994;343:727-28.
20. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;24:6-14.
21. Ahman DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG. Controlled evaluation of adriamycin in patients with disseminated breast cancer. Cancer Chemother Rep 1974;58: 877-82.
22. Clavel M, Catimel G. Breast cancer: chemotherapy in the treatment of advanced disease. Eur J Cancer 1993;29A:598-604.
23. Jones SE, Durie BG, Salmon SE. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer 1975;36:90-7.
24. Eddy DM. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992;10:657-70.
25. Porkka K, Blomqvist C, Rissanen P, Elomaa I, Pyrhönen S. Salvage therapy in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 1994;12:1639-47.
26. Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Felerabend C, et al. A phase 1 trial of 3 hour infusion of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor. Semin Oncol 1994;21:9-14.
27. Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Res 1994;24:6-14.
28. Perez EA. Paclitaxel in breast cancer. Oncologist 1998;3:373-89.
29. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-61.